Cargando…
Cannabinoids and their therapeutic applications in mental disorders
Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605020/ https://www.ncbi.nlm.nih.gov/pubmed/33162770 http://dx.doi.org/10.31887/DCNS.2020.22.3/pfadda |
_version_ | 1783604238008451072 |
---|---|
author | Scherma, Maria Muntoni, Anna Lisa Riedel, Gernot Fratta, Walter Fadda, Paola |
author_facet | Scherma, Maria Muntoni, Anna Lisa Riedel, Gernot Fratta, Walter Fadda, Paola |
author_sort | Scherma, Maria |
collection | PubMed |
description | Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study.
|
format | Online Article Text |
id | pubmed-7605020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-76050202020-11-06 Cannabinoids and their therapeutic applications in mental disorders
Scherma, Maria Muntoni, Anna Lisa Riedel, Gernot Fratta, Walter Fadda, Paola Dialogues Clin Neurosci Original Article Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study.
Les Laboratoires Servier 2020-09 /pmc/articles/PMC7605020/ /pubmed/33162770 http://dx.doi.org/10.31887/DCNS.2020.22.3/pfadda Text en © 2020, AICHServier GroupCopyright © 2020 AICH Servier Group. All rights reserved http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Scherma, Maria Muntoni, Anna Lisa Riedel, Gernot Fratta, Walter Fadda, Paola Cannabinoids and their therapeutic applications in mental disorders |
title | Cannabinoids and their therapeutic applications in mental disorders
|
title_full | Cannabinoids and their therapeutic applications in mental disorders
|
title_fullStr | Cannabinoids and their therapeutic applications in mental disorders
|
title_full_unstemmed | Cannabinoids and their therapeutic applications in mental disorders
|
title_short | Cannabinoids and their therapeutic applications in mental disorders
|
title_sort | cannabinoids and their therapeutic applications in mental disorders
|
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605020/ https://www.ncbi.nlm.nih.gov/pubmed/33162770 http://dx.doi.org/10.31887/DCNS.2020.22.3/pfadda |
work_keys_str_mv | AT schermamaria cannabinoidsandtheirtherapeuticapplicationsinmentaldisorders AT muntoniannalisa cannabinoidsandtheirtherapeuticapplicationsinmentaldisorders AT riedelgernot cannabinoidsandtheirtherapeuticapplicationsinmentaldisorders AT frattawalter cannabinoidsandtheirtherapeuticapplicationsinmentaldisorders AT faddapaola cannabinoidsandtheirtherapeuticapplicationsinmentaldisorders |